Neurodegenerative Disorders Research

Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
ABN: 86 139 590 319
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: enquiries@ndr.org.au
Web: www.ndr.org.au

Reach2HD

A Huntington's Disease Study

Aim

To assess the safety, tolerability and efficacy of two dose levels of PBT2 when administered orally once daily over 26 weeks in patients with early to mid-stage Huntington's disease.

Phase IIa

Randomized, double-blind, placebo-controlled, parallel group, multi-centre study (PBT2-203).

Hypothesis

Huntington's disease is an uncommon inherited disorder characterized by a combination of motor, cognitive and psychiatric symptoms that evolve over many years. PBT2 targets either the aggregation of huntingtin or the direct toxicity of mutant huntingtin protein through its interactions with copper and/or zinc and the restoration of neuronal metal homeostasis.

Status

Study completed

TGA Trial NCT01590888

Funding

- Prana Biotechnology Limited
- York Neuroscience Discovery Inc

Criteria

To be eligible for the Reach-2HD Study participants (male or female) must have:

- Total Functional Capacity (TFC 6-13)
- CAG repeat number of ≥ 36
- Montreal Cognitive Assessment (MoCA) score ≥ 12.

Ethics approval

Joondalup Health Campus Human Research Ethics Committee 1203.

Contact

Professor Peter K Panegyres
Principal Investigator

Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008

Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: research@ndr.org.au